Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 95 (3) , 693-707
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE studyTransplantation Research, 2013
- Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cellsStem Cell Research & Therapy, 2013
- Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; a pilot studyJournal of Translational Medicine, 2013
- DRhigh+CD45RA−-Tregs Potentially Affect the Suppressive Activity of the Total Treg Pool in Renal Transplant PatientsPLOS ONE, 2012
- Circulating lymphocyte subsets in different clinical situations after renal transplantationImmunology, 2012
- Mesenchymal stem cell effects on T-cell effector pathwaysStem Cell Research & Therapy, 2011
- Adipose-Derived Mesenchymal Stem Cell Protects Kidneys against Ischemia-Reperfusion Injury through Suppressing Oxidative Stress and Inflammatory ReactionJournal of Translational Medicine, 2011
- Identification of a B cell signature associated with renal transplant tolerance in humansJournal of Clinical Investigation, 2010
- Development of a cross-platform biomarker signature to detect renal transplant tolerance in humansJournal of Clinical Investigation, 2010
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006